Literature DB >> 33547461

Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.

Kobe C Yuen1, Li-Fen Liu1, Vinita Gupta1, Shravan Madireddi1, Shilpa Keerthivasan1, Congfen Li1, Deepali Rishipathak1, Patrick Williams1, Edward E Kadel1, Hartmut Koeppen1, Ying-Jiun Chen1, Zora Modrusan1, Jane L Grogan1, Romain Banchereau1, Ning Leng1, AnnChristine Thastrom1, Xiadong Shen1, Kenji Hashimoto2, Darren Tayama1, Michiel S van der Heijden3, Jonathan E Rosenberg4, David F McDermott5, Thomas Powles6, Priti S Hegde1, Mahrukh A Huseni7, Sanjeev Mariathasan8.   

Abstract

Entities:  

Year:  2021        PMID： 33547461     DOI： 10.1038/s41591-021-01246-4

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  2 in total

1.  Association of tumor molecular factors with in-transit metastasis in primary cutaneous melanoma.

Authors:  James W Jakub; Amy L Weaver; Alexander Meves
Journal:  Int J Dermatol       Date:  2022-03-05       Impact factor: 3.204

2.  Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model.

Authors:  Pan Li; Noah Rozich; Jianxin Wang; Junke Wang; Yao Xu; Brian Herbst; Raymond Yu; Stephen Muth; Nan Niu; Keyu Li; Vanessa Funes; Jessica Gai; Arsen Osipov; Barish H Edil; Christopher L Wolfgang; Ming Lei; Tingbo Liang; Lei Zheng
Journal:  Cancer Lett       Date:  2022-05-07       Impact factor: 9.756
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.